2025
4-Anilinoquinolinylchalcone derivatives mediate antifibrotic effects through ERK/MRTF—a signaling pathway crosstalk
Selvam P, Tseng C, Wang C, Sun Y, Chen Y, Kao Y, Dahms H, Cheng C. 4-Anilinoquinolinylchalcone derivatives mediate antifibrotic effects through ERK/MRTF—a signaling pathway crosstalk. Environmental Science And Pollution Research 2025, 32: 11685-11696. PMID: 40234319, DOI: 10.1007/s11356-025-36382-8.Peer-Reviewed Original ResearchConceptsSide effectsAbnormal liver functionAnti-fibrosisSevere side effectsGroup of drugsAnti-inflammatory responseHuman immune systemSkin rashGenitourinary cancersMechanism of actionAntifibrotic effectsBreast cancerScreened 6Immunomodulatory qualitiesLiver functionPharmacological profileImmune systemSignaling pathwaySignaling pathway crosstalkQuinolone analoguesCancerAnti-cancerDerivativesBleedingRashWorse clinical outcomes of TACE when liver function is decompensated in a cohort of patients with cirrhosis and HCC waiting for liver transplantation
Makarova E, Fan X, Farooqi I, Bakhl K, Murphy T, Stonesifer E, Faust A. Worse clinical outcomes of TACE when liver function is decompensated in a cohort of patients with cirrhosis and HCC waiting for liver transplantation. Journal Of Liver Transplantation 2025, 17: 100257. DOI: 10.1016/j.liver.2024.100257.Peer-Reviewed Original ResearchTrans arterial chemoembolizationDecompensated liver functionHepatocellular carcinomaLiver functionLiver transplantationClinical outcomesRetrospective cohort study of patientsClinical outcomes of patientsWorsening of liver functionCohort study of patientsCompensated liver functionOutcomes of patientsCohort of patientsRetrospective cohort studyStudy of patientsStatistically significant differenceLocoregional therapyArterial chemoembolizationDecompensated cirrhosisPoor outcomePrimary statistical analysisPatientsCirrhosisTransplantationSignificant difference
2024
Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Njei B, Al-Ajlouni Y, Lemos S, Ugwendum D, Ameyaw P, Njei L, Boateng S. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus 2024, 16: e71366. PMID: 39534801, PMCID: PMC11556413, DOI: 10.7759/cureus.71366.Peer-Reviewed Original ResearchRandomized Controlled TrialsGLP-1RAsReceptor agonistsSafety of GLP-1 receptor agonistsLiver functionLiver diseaseGlucagon-like peptide-1 receptor agonistsMeta-analysis of randomized controlled trialsSteatotic liver diseasePeptide-1 receptor agonistsControlled TrialsGLP-1 receptor agonistsMeta-analysisMeta-analyze randomized controlled trialsRevised Cochrane Risk of Bias ToolAssociated with significant reductionsPromote weight lossImprove liver functionCardiovascular risk factorsCochrane risk of bias toolRisk of bias toolRandom-effects modelHepatic outcomesHepatic function markersGLP-1RASelenomethionine supplementation mitigates fluoride-induced liver apoptosis and inflammatory reactions by blocking Parkin-mediated mitophagy in mice
Wang T, Li H, Li Y, Li M, Zhao H, Zhang W, Zhao T, Wang Y, Wang J, Wang J. Selenomethionine supplementation mitigates fluoride-induced liver apoptosis and inflammatory reactions by blocking Parkin-mediated mitophagy in mice. The Science Of The Total Environment 2024, 951: 175458. PMID: 39142410, DOI: 10.1016/j.scitotenv.2024.175458.Peer-Reviewed Original ResearchParkin-mediated mitophagyCysteinyl aspartate specific proteinase 3Protein expression levelsLight chain 3Expression levelsInterleukin-6Wild-typeLiver damageContents of proinflammatory factorsTumor necrosis factor-aNuclear factor kappa BLevels of liver functionMitochondrial fusionFactor kappa BParkin-/-Inflammatory signaling pathwaysMicrotubule-associated protein light chain 3MitophagyInterferon-gMitochondrial alterationsProtein light chain 3Gene knockoutIFN-gFluorosis miceLiver functionRole of ammonia and glutamine in the pathogenesis and progression of metabolic dysfunction‐associated steatotic liver disease: A systematic review
Njei B, Al-Ajlouni Y, Ameyaw P, Njei L, Boateng S. Role of ammonia and glutamine in the pathogenesis and progression of metabolic dysfunction‐associated steatotic liver disease: A systematic review. Journal Of Gastroenterology And Hepatology 2024, 39: 1788-1808. PMID: 38763916, DOI: 10.1111/jgh.16603.Peer-Reviewed Original ResearchConceptsClinical trialsLiver diseaseSteatotic liver diseaseSystematic reviewPersonalized approach to treatmentLarge-scale clinical trialsHuman clinical trialsUrea cycle dysfunctionApproach to treatmentPreclinical findingsPotential therapeutic targetHepatocellular carcinomaLiver cirrhosisLiver functionMeticulous searchDisease progressionSearch of literatureVariable expressionHuman studiesPROSPERO databaseExpression of glutamine synthetaseTherapeutic interventionsPRISMA guidelinesTherapeutic targetMetabolic differencesHeavy metals and metalloids exposure and liver function in Chinese adults — A nationally representative cross-sectional study
Wang S, Lyu Y, Ji S, Liu N, Wu B, Zhao F, Li Z, Qu Y, Zhu Y, Xie L, Li Y, Zhang Z, Song H, Hu X, Qiu Y, Zheng X, Zhang W, Yang Y, Li F, Cai J, Zhu Y, Cao Z, Tan F, Shi X. Heavy metals and metalloids exposure and liver function in Chinese adults — A nationally representative cross-sectional study. Environmental Research 2024, 252: 118653. PMID: 38518907, DOI: 10.1016/j.envres.2024.118653.Peer-Reviewed Original ResearchHeavy metalsEffects of heavy metalsChinese adultsHuman biomonitoring surveyMetalloid exposureBiomonitoring surveysEnvironmental presenceSample of Chinese adultsBenefits of seleniumCross-sectional studyHigher concentrationsNo significant associationMetalloidsLiver functionAspartate aminotransferaseAlcohol consumptionAlanine aminotransferaseAlcohol intakeSeleniumManganeseSignificant associationHealthMetalLiver healthAnalyzed dataAssociation of a dietary inflammatory index with cardiometabolic, endocrine, liver, renal and bones biomarkers: cross-sectional analysis of the UK Biobank study
Carrasco-Marín F, Zhao L, Hébert J, Wirth M, Petermann-Rocha F, Phillips N, Malcomson F, Mathers J, Ferguson L, Ho F, Pell J, Celis-Morales C, Molina-Recio G, Molina-Luque R. Association of a dietary inflammatory index with cardiometabolic, endocrine, liver, renal and bones biomarkers: cross-sectional analysis of the UK Biobank study. Nutrition Metabolism And Cardiovascular Diseases 2024, 34: 1731-1740. PMID: 38664123, DOI: 10.1016/j.numecd.2024.03.010.Peer-Reviewed Original ResearchConceptsPro-inflammatory dietLiver functionUK Biobank participantsUK Biobank studyHealthy individualsDiet Inflammatory IndexDietary inflammatory indexCross-sectional studyCross-sectional analysisAnti-inflammatory dietBiobank participantsBiobank studyCardiometabolic healthChronic diseasesInflammatory indexRenal functionBone biomarkersProfiles of biomarkersBone healthMetabolic biomarkersCardiometabolicRenal markersIGF-1Metabolic healthTotal cholesterolEx situ liver resection for intrahepatic cholangiocarcinoma: survival analysis and comparison to systemic chemotherapy
Nieddu E, Billato I, Peluso C, Furlanetto A, Lazzari S, D'Amico F, Cillo U, Gringeri E. Ex situ liver resection for intrahepatic cholangiocarcinoma: survival analysis and comparison to systemic chemotherapy. Digestive And Liver Disease 2024, 56: s42. DOI: 10.1016/j.dld.2024.01.067.Peer-Reviewed Original ResearchProgression-free survivalCA19-9 levelsEx situ liver resectionOverall survivalIntrahepatic cholangiocarcinomaEx situ surgeryStage of diseasePerformance statusSystemic chemotherapySurgical resectionLiver resectionLiver functionHigh-volume hepatobiliary centersLower stage of diseaseMedian progression-free survivalTreated with surgical resectionEvaluate long-term outcomesSurvival analysisEx situ resectionNon-parametric log-rank testTreated with chemotherapyLog-rank testLiver function testsCox regression analysisLong-term outcomesPredicting Safe Liver Resection Volume for Major Hepatectomy Using Artificial Intelligence
Kang C, Ku H, Moon H, Kim S, Jo J, Choi Y, Shin D. Predicting Safe Liver Resection Volume for Major Hepatectomy Using Artificial Intelligence. Journal Of Clinical Medicine 2024, 13: 381. PMID: 38256518, PMCID: PMC10816299, DOI: 10.3390/jcm13020381.Peer-Reviewed Original ResearchPost-hepatectomy liver failureResection volumeLiver functionRisk of post-hepatectomy liver failureApplication of artificial intelligencePreoperative liver functionPatient's liver functionLiver resection volumeComputed tomography scanCause of morbidityField of liver surgeryImproving clinical outcomesMajor hepatectomyLiver resectionResection limitLiver volumetryLiver surgeryTomography scanClinical outcomesLiver failureSurgical planningPatient characteristicsResectionArtificial intelligencePatients
2023
Maresin1 prevents sepsis-induced acute liver injury by suppressing NF-κB/Stat3/MAPK pathways, mitigating inflammation
Sun S, Wang L, Wang J, Chen R, Pei S, Yao S, Lin Y, Yao C, Xia H. Maresin1 prevents sepsis-induced acute liver injury by suppressing NF-κB/Stat3/MAPK pathways, mitigating inflammation. Heliyon 2023, 9: e21883. PMID: 38027581, PMCID: PMC10665730, DOI: 10.1016/j.heliyon.2023.e21883.Peer-Reviewed Original ResearchSepsis-induced acute liver injuryAcute liver injuryAnti-inflammatory effectsLiver injuryNeutrophil infiltrationBacterial loadSurvival rateDocosahexaenoic acidNormal saline 1Peritoneal lavage fluidPro-inflammatory moleculesTreatment of sepsisUncontrolled inflammatory responseAnti-inflammatory moleculesSepsis-induced injuryEffects of MaR1Body weight changesSepsis-related diseasesDose-dependent mannerSaline 1Septic miceCecal ligationLavage fluidLiver functionAcute inflammationSafety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis
Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, Torres M, Strazzabosco M, Giannini E. Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis. Liver Cancer 2023, 13: 235-245. PMID: 38756146, PMCID: PMC11095597, DOI: 10.1159/000533991.Peer-Reviewed Original ResearchChild-Pugh class B patientsChild-Pugh B patientsClass B patientsObjective response rateProgression-free survivalChild-Pugh AB patientsOverall survivalHepatocellular carcinomaAdverse eventsLiver functionOdds ratioChild-Pugh class A patientsTreatment-related adverse eventsChild-Pugh class AHigher objective response rateShorter progression-free survivalMedian overall survivalAlbumin-bilirubin gradeImpaired liver functionClass A patientsUnresectable hepatocellular carcinomaIndividualization of treatmentChild-PughALBI gradeSystematic review and meta-analysis of safety and efficacy of atezolizumab/ bevacizumab in Child-Pugh class B patients with hepatocellular carcinoma
Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, Torres M, Strazzabosco M, Giannini E. Systematic review and meta-analysis of safety and efficacy of atezolizumab/ bevacizumab in Child-Pugh class B patients with hepatocellular carcinoma. Digestive And Liver Disease 2023, 55: s221. DOI: 10.1016/j.dld.2023.08.025.Peer-Reviewed Original ResearchChild-Pugh class B patientsClass B patientsDisease control rateObjective response rateImpaired liver functionB patientsHepatocellular carcinomaLiver functionChild-Pugh B cirrhosisTreatment-related adverse eventsHigher objective response rateAdverse events gradeBest supportive careMedian overall survivalProgression-free survivalIndividualization of treatmentClass AB cirrhosisChild-PughCohort studyFree survivalOverall survivalSupportive careAdverse eventsOncological efficacyA Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1
Weiss S, Sznol M, Shaheen M, Berciano-Guerrero M, Couselo E, Rodríguez-Abreu D, Boni V, Schuchter L, Gonzalez-Cao M, Arance A, Wei W, Ganti A, Hauke R, Berrocal A, Iannotti N, Hsu F, Kluger H. A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1. Clinical Cancer Research 2023, 30: 74-81. PMID: 37535056, PMCID: PMC10767304, DOI: 10.1158/1078-0432.ccr-23-0475.Peer-Reviewed Original ResearchConceptsObjective response ratePhase II trialAdverse eventsPartial responseDisease progressionII trialGrade 3 adverse eventsAnti PD-1CD40 agonist antibodyElevated liver functionTreatment-related SAEsCommon adverse eventsActivation of CD40Subset of patientsFavorable safety profileAntigen presenting cellsStable diseaseMedian durationAdvanced melanomaAdditional patientsLiver functionSafety profileMetastatic melanomaPreclinical dataPresenting cellsPhysiologically-based pharmacokinetic (PBPK) modeling of sodium fluorescein (SF) blood clearance for assessing hepatic ischemia-reperfusion injury (IRI)
Monti C, Womack J, Audi S, Hong S, Yang Y, Kim J, Dash R. Physiologically-based pharmacokinetic (PBPK) modeling of sodium fluorescein (SF) blood clearance for assessing hepatic ischemia-reperfusion injury (IRI). Physiology 2023, 38: 5732857. DOI: 10.1152/physiol.2023.38.s1.5732857.Peer-Reviewed Original ResearchIschemia-reperfusion injuryIschemia-reperfusion injury conditionsMRP2 activityBlood clearanceSodium fluoresceinPBPK modelSF concentrationsEffects of ischemia-reperfusion injuryContribution of Mrp2Hepatic ischemia-reperfusion injuryWarm ischemia timeActivity of MRP2Bile-to-plasmaDiminished secretionIschemia timeMRP2 transportersCanalicular transportersLiver functionMRP2Intracellular internalizationBloodBileClearance dataClearanceLiver
2022
Oridonin ameliorates acetaminophen‐induced acute liver injury through ATF4/PGC‐1α pathway
Yu D, Li J, Wang Y, Guo D, Zhang X, Chen M, Zhou Z. Oridonin ameliorates acetaminophen‐induced acute liver injury through ATF4/PGC‐1α pathway. Drug Development Research 2022, 84: 211-225. PMID: 36567664, DOI: 10.1002/ddr.22024.Peer-Reviewed Original ResearchConceptsAcute liver injuryPGC-1α pathwayLiver injuryCytochrome P450 2E1 (CYP2E1) levelsEndoplasmic reticulum stress activationOxidative stressP450 2E1 levelsImproved liver functionPotential therapeutic effectsPGC-1α levelsHepatocyte cell deathUnclear molecular mechanismsLiver functionProinflammatory cytokinesHepatic toxicityHepatoprotective effectTherapeutic effectAPAP metabolismATF4 knockdownNecrotic areasWestern blotAPAPMetabolic activationMitochondrial dysfunctionProtein levelsEpigenome-wide association study of biomarkers of liver function identifies albumin-associated DNA methylation sites among male veterans with HIV
Titanji BK, Lee M, Wang Z, Chen J, Hui Q, Re V, So-Armah K, Justice AC, Xu K, Freiberg M, Gwinn M, Marconi VC, Sun YV. Epigenome-wide association study of biomarkers of liver function identifies albumin-associated DNA methylation sites among male veterans with HIV. Frontiers In Genetics 2022, 13: 1020871. PMID: 36303554, PMCID: PMC9592923, DOI: 10.3389/fgene.2022.1020871.Peer-Reviewed Original ResearchLiver diseaseLiver biomarkersLiver functionDNAm age accelerationAge accelerationVeterans Aging Cohort StudyEpigenome-wide association studiesFIB-4 scoreAging Cohort StudyMale PWHAPRI scoreCohort studyPlatelet countTotal bilirubinAlanine transaminaseClinical dataBlood samplesIndependent cohortSerum albuminMale veteransHIVImportant causeSignificant associationPWHDNAm sitesHolistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook
Jaffe A, Taddei TH, Giannini EG, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver International 2022, 42: 2607-2619. PMID: 36161463, PMCID: PMC10878125, DOI: 10.1111/liv.15432.Peer-Reviewed Original ResearchConceptsLiver diseaseHepatocellular carcinomaLiver functionRisk factorsRelevant prognostic roleChronic hepatitis BResidual liver functionChronic liver diseaseManagement of patientsCare of patientsCommon risk factorsAppropriate surveillance strategiesSuccessful cancer treatmentC infectionCommon complicationHepatitis BMetabolic syndromePrognostic roleSignificant morbidityLongitudinal careCurrent careCancer recurrenceHCC managementLiver cancerHCC treatmentDragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy
Korenblik R, Olij B, Aldrighetti LA, Hilal MA, Ahle M, Arslan B, van Baardewijk LJ, Baclija I, Bent C, Bertrand CL, Björnsson B, de Boer MT, de Boer SW, Bokkers RPH, Rinkes IHMB, Breitenstein S, Bruijnen RCG, Bruners P, Büchler MW, Camacho JC, Cappelli A, Carling U, Chan BKY, Chang DH, choi J, Font JC, Crawford M, Croagh D, Cugat E, Davis R, De Boo DW, De Cobelli F, De Wispelaere JF, van Delden OM, Delle M, Detry O, Díaz-Nieto R, Dili A, Erdmann JI, Fisher O, Fondevila C, Fretland Å, Borobia FG, Gelabert A, Gérard L, Giuliante F, Gobardhan PD, Gómez F, Grünberger T, Grünhagen DJ, Guitart J, Hagendoorn J, Heil J, Heise D, Herrero E, Hess GF, Hoffmann MH, Iezzi R, Imani F, Nguyen J, Jovine E, Kalff JC, Kazemier G, Kingham TP, Kleeff J, Kollmar O, Leclercq WKG, Ben SL, Lucidi V, MacDonald A, Madoff DC, Manekeller S, Martel G, Mehrabi A, Mehrzad H, Meijerink MR, Menon K, Metrakos P, Meyer C, Moelker A, Modi S, Montanari N, Navines J, Neumann UP, Peddu P, Primrose JN, Qu X, Raptis D, Ratti F, Ridouani F, Rogan C, Ronellenfitsch U, Ryan S, Sallemi C, Moragues JS, Sandström P, Sarriá L, Schnitzbauer A, Serenari M, Serrablo A, Smits MLJ, Sparrelid E, Spüntrup E, Stavrou GA, Sutcliffe RP, Tancredi I, Tasse JC, Udupa V, Valenti D, Fundora Y, Vogl TJ, Wang X, White SA, Wohlgemuth WA, Yu D, Zijlstra IAJ, Binkert CA, Bemelmans MHA, van der Leij C, Schadde E, van Dam RM. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy. CardioVascular And Interventional Radiology 2022, 45: 1391-1398. PMID: 35790566, PMCID: PMC9458562, DOI: 10.1007/s00270-022-03176-1.Peer-Reviewed Original ResearchConceptsFuture liver remnant hypertrophyHepatic vein embolizationMulticenter prospective single-arm trialResectable colorectal cancer liver metastasesColorectal cancer liver metastasesProspective single-arm trialFeasibility of resectionCancer liver metastasesDisease-free survivalSingle-arm trialSmall FLRPrimary endpointSecondary endpointsFLR hypertrophyLiver metastasesOverall survivalProspective trialVein embolizationLiver functionSafety profileArm trialLiver volumeWeek 1Week 3Study centersFluorescein clearance kinetics in blood and bile indicates hepatic ischemia-reperfusion injury in rats
Kim J, Yang Y, Hong S, Zielonka J, Dash R, Audi S, Kumar S, Joshi A, Zimmerman M, Hong J. Fluorescein clearance kinetics in blood and bile indicates hepatic ischemia-reperfusion injury in rats. AJP Gastrointestinal And Liver Physiology 2022, 323: g126-g133. PMID: 35700191, DOI: 10.1152/ajpgi.00038.2022.Peer-Reviewed Original ResearchConceptsWarm ischemia timeHepatic ischemia-reperfusion injuryIschemia-reperfusion injuryBile-to-plasmaClearance kineticsWarm ischemia time groupsSprague-Dawley ratsBile metabolismMeasured 1 hSodium fluorescein injectionFluorescein injectionIschemia timeLiver functionTherapeutic strategiesSodium fluoresceinInverse correlationDecreased levelsBloodBileBile samplesFluorescence ratioReperfusionRatsFluoresceinIncreased levelsDiagnostik und intraarterielle Therapien primärer Lebertumoren
Becker L, Wacker F, Hinrichs J. Diagnostik und intraarterielle Therapien primärer Lebertumoren. Die Onkologie 2022, 28: 308-317. DOI: 10.1007/s00761-022-01117-8.Peer-Reviewed Original ResearchIntrahepatic cholangiocellular carcinomaMagnetic resonance imagingCross-sectional imagingAssessment of HCCConclusionsContrast-enhanced magnetic resonance imagingAdequate liver functionPrimary liver tumorsIntra-arterial proceduresHepatocyte-specific contrast agentPrimary liver cancerOverview of epidemiologyInoperable diseaseTumor characteristicsInoperable cancerSurvival benefitCholangiocellular carcinomaTherapy optionsLiver tumorsTreatment optionsIntra-arteriallyClinical symptomsTimely diagnosisBackgroundHepatocellular carcinomaLiver functionInterventional radiology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply